drugset
drugset / Trial / NCT02524951

Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer

NCT02524951 ↗

Phase 1 Terminated 5 enrolled Northwell Health DepYmed Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase I, open-label, dose escalation study. MSI-1436 will be administered as a single intravenous infusion twice a week for 3 weeks on a 4-week cycle.

Timeline

Start
2016-04
Primary completion
2017-07
Completion
2018-05-14

Outcome

Outcome not reported

Stopped: “lack of interest by sponsor”

Drugs

EvaluationDrugModalityDoseRoute
Subject MSI-1436C Unknown 20 mg/m2 Intravenous
Subject MSI-1436C Unknown 26 mg/m2 Intravenous
Subject MSI-1436C Unknown 34 mg/m2 Intravenous
Subject MSI-1436C Unknown 44 mg/m2 Intravenous
Subject MSI-1436C Unknown 57 mg/m2 Intravenous
Subject MSI-1436C Unknown 74 mg/m2 Intravenous
Subject MSI-1436C Unknown 96 mg/m2 Intravenous

Indications

breast cancer